Bagsværd, Denmark, 24 April 2018 - At Novo Nordisk's Annual General Meeting on 22 March 2018, it was decided to reduce the company's B share capital from DKK 392,512,800 to DKK 382,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 490,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 382,512,800.
The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com (mailto:amhg@novonordisk.com) |
| Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com (mailto:kiau@novonordisk.com) |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com (mailto:phak@novonordisk.com) |
| Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com (mailto:armk@novonordisk.com) |
| Christina Kjær | +45 3079 3009 | cnje@novonordisk.com (mailto:cnje@novonordisk.com) |
Company announcement No 34 / 2018
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
